Last reviewed · How we verify
Entonox
At a glance
| Generic name | Entonox |
|---|---|
| Also known as | Oxygen 50.0% +/- 2.0%, Nitrous oxide 50.0% +/- 2.0%, Entonox gas, Laughing gas |
| Sponsor | University of Oxford |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Nitrous Oxide and EMOtional Cognition (NA)
- Anxiolysis for Laceration Repair in Children (PHASE3)
- CODEPAD (Collaborative Outcomes of DEpression and Pain Associated With Delivery) (PHASE2, PHASE3)
- The Effect of Entonox on Stages of Labor in Nulliparous Women (NA)
- A Single-centre Study of Entonox Versus Midazolam Sedation in Gastroscopy (PHASE4)
- Effect of Hot Pack on Labor Pain, Duration of Labor, and Satisfaction of Primigravidae Women in Saudi Arabia (NA)
- Nitrous Oxide for External Cephalic Version (PHASE3)
- Optimizing the Use of Entonox® During Screening Colonoscopy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Entonox CI brief — competitive landscape report
- Entonox updates RSS · CI watch RSS
- University of Oxford portfolio CI